Medical Information
In order to provide you with relevant and meaningful content we need to know more about you.
Please choose the category that best describes you.
This content is intended for U.S. Healthcare Professionals. Would you like to proceed?
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Depo-Provera CI is supplied in the following strengths and package configurations:
| Package Configuration | Strength | NDC |
|---|---|---|
| Depo-Provera CI (medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) | ||
| 1 mL vial | 150 mg/mL | NDC 0009-0746-30 |
| 25 × 1 mL vials | 150 mg/mL | NDC 0009-0746-35 |
| Depo-Provera CI prefilled syringes packaged with 22 gauge × 1 1/2 inch Terumo® SurGuard™ Needles | ||
| 1 mL prefilled syringe | 150 mg/mL | NDC 0009-7376-11 |
To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at